Developer docs
API playgroundTry for free, no card

Search company profiles

Noventure

Full company profile

uuid000fiii

Namestring
Noventure
Legal namestring
Noventure, S.L.
Websiteurl
noventure.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Noventure, S.L. is a Barcelona-based medical device IP company that develops and licenses clinically backed healthcare brands built on a proprietary barrier technology platform. The company's core technology rests on natural polymers — xyloglucan, gelatin tannate, gelose, and Olea europaea leaf extract — that form protective films over mucosal epithelia and modulate wound microenvironments, addressing acute diarrhea (Tasectan AF, Tasectan Duo, Xilaplus AF), uncomplicated urinary tract infections (Utipro Plus AF), anal fissure healing (Ulkox), IBS-D (Gelsectan), rhinitis (Rhinosectan), and hard-to-heal skin ulcers (Oleoabrax EHO). All primary products are CE-marked and comply with MDR Class III (or Class IIb for Ulkox), and the products are supported by randomized controlled trials with two included in leading European treatment guidelines (EAU cystitis guidelines, German GPGN pediatric gastroenterology guidelines).

The company operates an asset-light licensing model and does not sell directly. Noventure grants exclusive territorial commercial rights to regional distribution partners (Devicare in Spain, RFSU in the Nordics, Pharmaforce across Denmark/Sweden/Finland/Norway, Salvat in Iberia, Therabel in France, Montavit in Austria, Jadran in Russia, Medexport in Kazakhstan, and others), and partners commercialize products through pharmacy channels under local brand names. Products reach over 50 countries and the Tasectan franchise alone sold 3.7 million packs (51+ million standard units) through licensees in 34 countries during 2023.

Noventure is privately held, was founded in 2014, has 11-50 employees, and discloses no institutional ownership or parent company. The customer base is B2B — distribution partners rather than end users — and revenue derives from licensing royalties on partner net sales. Geographic and therapeutic-area expansion is active, with new registrations in Central Asia (2025), recent licensee additions across Eastern Europe, and continued portfolio broadening via the 2021 acquisition of Ulkox and Oleoabrax wound-healing products.

Short descriptiontext

Noventure is a Barcelona-based medical device IP company that licenses clinically backed, MDR Class III-certified brands (Tasectan, Utipro Plus, Ulkox) built on proprietary natural-polymer barrier technology to exclusive distribution partners across 50+ countries, addressing diarrhea, UTIs, and wound care via pharmacy channels.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBarcelona, Spain
HQ citystring
Barcelona
HQ countrystring
Spain
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medical devices, barrier technology products, gastrointestinal therapeutics, urogynecology treatments, wound healing devices
Industry2 codes
PRIMARYHLAIAJAB
Specialty Pharmaceutical Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYHLAIACAH
Nephrology & Urology Specialty Pharmaceuticals
NAICS code2 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Drugs and Druggists' Sundries Merchant Wholesalers42421
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Medical Devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Licensing Royalties
TypeLicensing Royalties
Description

Noventure's business model is based on licensing exclusive commercial rights for medical device products to distribution partners in selected geographic regions. Partners commercialize products under various local brand names and pay licensing fees or royalties to Noventure.

noventure.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Operations, Marketing or Sales, Personnel, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 9 records shown
1Tasectan
Description

Medical device for treatment of acute diarrhoea, composed of xyloglucan and gelose. MDR Class III certified.

noventure.com
+8 more records
Core offering1 text field

Noventure develops, patents, and licenses a portfolio of CE-marked, MDR Class III medical devices based on proprietary barrier technology using natural polymers (xyloglucan, gelatin tannate, gelose, Olea europaea leaf extract). Core products treat acute diarrhoea (Tasectan AF), urinary tract infections (Utipro Plus AF), and anal fissures (Ulkox), with additional wound-healing, nasal, and IBS-D products. The company does not sell directly; instead it grants exclusive commercial distribution rights to regional pharmaceutical partners who commercialize the products under local brand names through pharmacies in over 50 countries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Tasectan demonstrated reduction of stool frequency and improved stool consistency in children with acute diarrhea in randomized controlled trials
+2 more records
Product overview1 text field

Noventure is a Barcelona-based medical device company operating a multi-brand portfolio of clinically proven healthcare products. The core portfolio consists of three primary CE-marked medical devices: Tasectan AF (MDR Class III) for acute diarrhea, Utipro Plus AF (MDR Class III) for urinary tract infections, and Ulkox (MDR Class IIb) for anal fissure healing. All products are backed by clinical trials, included in treatment guidelines, and protected by patents. The company also markets acquired wound-healing products (Oleoabrax EHO), nasal mucoprotection (Rhinosectan), pediatric diarrhea formulations (Xilaplus AF), probiotic combinations (Tasectan Duo), and IBS-D treatment (Gelsectan). Noventure's business model is based on licensing distribution rights to regional partner companies, with products distributed across over 50 countries.

Product and service6 records
1Tasectan AF
CategoryMedical Device - Gastroenterology
Description

CE-marked, MDR Class III medical device composed of xyloglucan (tamarind seed extract) and gelose that forms a protective film over the intestinal mucosa to reduce frequency and duration of acute diarrhoea in children (under 3 years up to 14 years, sachets) and adults (capsules). Licensed to exclusive distribution partners worldwide.

2Utipro Plus AF
CategoryMedical Device - Urology
Description

CE-marked, MDR Class III medical device based on xyloglucan and gelose that creates a protective mechanical barrier in the intestinal lumen to impair bacterial contact with mucosa, prevent adhesion of uropathogenic bacteria, and reduce recurrent urinary tract infections in adolescents (14+ years) and adults. Mentioned in EAU guidelines as non-antibiotic approach with highest level of scientific evidence.

3Ulkox
CategoryMedical Device - Proctology / Wound Care
Description

CE-marked, MDR Class IIb medical device based on Fucocert (polysaccharide), glycerine, Olea europaea leaf extract, and Carbopol 980 presented as hydrogel for the healing of anal fissures in children and adults. Components act synergistically by moisturizing the wound, scavenging free radicals, isolating the lesion, and reducing pH.

4Oleoabrax EHO
CategoryMedical Device - Wound Care / Dermatology
Description

CE-marked medical device based on Olea europaea leaf extract hydrogel (EHO-85) intended for healing of full and partial thickness wounds including pressure ulcers, venous leg ulcers, and diabetic foot ulcers. Demonstrated 51.6% relative wound area reduction versus 18.9% for standard hydrogel in clinical trials.

5Rhinosectan
CategoryMedical Device - Allergy / ENT
Description

Class I CE-marked medical device based on xyloglucan (mucomimetic agent) that forms a protective barrier over the nasal epithelial mucosa for control and treatment of rhinitis and rhinosinusitis symptoms.

6Xilaplus AF
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership15 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2018-02-22
Description

Salvat distributes Noventure's nasal mucoprotection product (Rhinosectan) in Spain and Portugal. The product is a Class I CE marked medical device based on xyloglucan for control and treatment of rhinitis and rhinosinusitis symptoms.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2017-03-13
Description

RFSU distributes Noventure's Utipro Plus in Nordic countries (Denmark, Finland, Iceland, Norway and Sweden). With this agreement, Utipro Plus became available in 21 European countries. RFSU is a Swedish Association for Sexuality Education and NGO founded in 1933, focused on women's health.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

New partnership announced to bring Utipro Plus AF into the Spanish market. Noventure collaborates with Devicare to expand product availability in Spain.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Noventure granted Pharmaforce exclusive distribution right for Tasectan AF in the Nordic markets (Denmark, Sweden, Finland, and Norway). Tasectan AF is intended to restore physiological functions of intestinal walls for control and reduction of diarrheal events.

Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Vemedia distributes Utipro Plus in the Netherlands and France (under the umbrella brand Cysticare/Utipro plus).

Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Lapidot is a long-term distribution partner for Utipro Plus in Israel since Q4 2017.

7JGL
Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

JGL distributes Tasectan in Croatia under the brand Normia Stop. Tasectan acts by forming a film that protects intestinal mucosa, reducing frequency and duration of diarrhea episodes.

noventure.com
Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Therabel is a long-term partner distributing Xilaplus in France under the brand name Diastil Diarrhee.

Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

New partnership with Generica Ilaç to market Xilaplus AF in Turkey. Xilaplus AF is a Class IIa CE marked medical device for control and reduction of diarrheal events.

10Medexport
Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Medexport signed an agreement for distribution of Utipro Plus AF in Kazakhstan, representing expansion into Central Asia.

noventure.com
Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Pamex extends distribution of Utipro Plus AF to the UK, building on their existing partnership in Ireland.

Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Miecys distributes Xilaplus in Estonia, Latvia, and Lithuania.

Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Montavit distributes Tasectan Duo in Austria (second market after Italy by Angelini). Tasectan Duo is the first combination of gelatin tannate and inactivated bacteria.

14Jadran
Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Jadran distributes Tasectan in Russia under the umbrella brand Adiarin. It was the first Noventure product launched in Russia.

noventure.com
Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

ELVA launches Utipro Plus in Czech Republic, Slovak Republic, and Hungary.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Swiss specialty pharma with strong focus on gastroenterology, urology, and reproductive health — directly overlapping with Noventure's therapeutic categories. Comparable specialty-pharma profile with patent-protected products and a global licensing/partner approach.

TypeDirect peer
Description

Swiss specialty pharma focused on gastroenterology (IBD, infectious diarrhea). Comparable size to Noventure with a similar specialty medical-device product strategy and European licensing/commercial model.

TypeBroad incumbent
Description

Italian pharmaceutical group with strong consumer health and distribution network across Europe and emerging markets. Comparable mid-to-large European specialty pharma with deep licensing and distribution partnerships.

TypeBroad incumbent
Description

Spanish specialty pharma with focus on dermatology and specialty care. Comparable as a Spanish-headquartered specialty pharma with European commercial reach and licensing partnerships in adjacent therapeutic areas.

TypeBroad incumbent
Description

Italian specialty pharma with focus on women's health, neurology, and rare diseases. Comparable specialty/OTC profile and European licensing approach, particularly relevant for women's health (UTIs).

6BioGaia AB
TypeDirect peer
Description

Swedish probiotics and gut-health consumer healthcare company. Comparable in therapeutic focus (gut health), consumer/medical positioning, and global partner-driven distribution model with multiple brand SKUs.

TypeBroad incumbent
Description

Italian specialty pharma with focus on respiratory, neonatology, and rare diseases. Comparable European specialty-pharma profile and global licensing/partner approach.

TypeBroad incumbent
Description

Global medical device company with a significant wound management franchise. Comparable to Noventure's wound-care portfolio (Ulkox/Oleoabrax) in the chronic-wound-care segment, though much larger scale.

TypeBroad incumbent
Description

Italian specialty pharma with consumer health/OTC portfolio and licensing partnerships. Comparable specialty-medtech and licensing-driven distribution model across Europe and the Mediterranean.

TypeBroad incumbent
Description

Italian specialty pharma with European focus on rare diseases, urology, and specialty care. Comparable specialty pharma of similar size range operating through licensing and partner distribution in Europe.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Noventure

Medical Devicesnoventure.com

Noventure is a Barcelona-based medical device IP company that licenses clinically backed, MDR Class III-certified brands (Tasectan, Utipro Plus, Ulkox) built on proprietary natural-polymer barrier technology to exclusive distribution partners across 50+ countries, addressing diarrhea, UTIs, and wound care via pharmacy channels.

What Noventure does

Noventure, S.L. is a Barcelona-based medical device IP company that develops and licenses clinically backed healthcare brands built on a proprietary barrier technology platform. The company's core technology rests on natural polymers — xyloglucan, gelatin tannate, gelose, and Olea europaea leaf extract — that form protective films over mucosal epithelia and modulate wound microenvironments, addressing acute diarrhea (Tasectan AF, Tasectan Duo, Xilaplus AF), uncomplicated urinary tract infections (Utipro Plus AF), anal fissure healing (Ulkox), IBS-D (Gelsectan), rhinitis (Rhinosectan), and hard-to-heal skin ulcers (Oleoabrax EHO). All primary products are CE-marked and comply with MDR Class III (or Class IIb for Ulkox), and the products are supported by randomized controlled trials with two included in leading European treatment guidelines (EAU cystitis guidelines, German GPGN pediatric gastroenterology guidelines).

The company operates an asset-light licensing model and does not sell directly. Noventure grants exclusive territorial commercial rights to regional distribution partners (Devicare in Spain, RFSU in the Nordics, Pharmaforce across Denmark/Sweden/Finland/Norway, Salvat in Iberia, Therabel in France, Montavit in Austria, Jadran in Russia, Medexport in Kazakhstan, and others), and partners commercialize products through pharmacy channels under local brand names. Products reach over 50 countries and the Tasectan franchise alone sold 3.7 million packs (51+ million standard units) through licensees in 34 countries during 2023.

Noventure is privately held, was founded in 2014, has 11-50 employees, and discloses no institutional ownership or parent company. The customer base is B2B — distribution partners rather than end users — and revenue derives from licensing royalties on partner net sales. Geographic and therapeutic-area expansion is active, with new registrations in Central Asia (2025), recent licensee additions across Eastern Europe, and continued portfolio broadening via the 2021 acquisition of Ulkox and Oleoabrax wound-healing products.

Noventure firmographics

Firmographics
Name
Noventure
Legal name
Noventure, S.L.
Website
https://noventure.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
Noventure is a Barcelona-based medical device IP company that licenses clinically backed, MDR Class III-certified brands (Tasectan, Utipro Plus, Ulkox) built on proprietary natural-polymer barrier technology to exclusive distribution partners across 50+ countries, addressing diarrhea, UTIs, and wound care via pharmacy channels.
Ownership category
akta.pro rank

Noventure industry classification

Industry
Product category
Medical Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112), Drugs and Druggists' Sundries Merchant Wholesalers (42421)
SIC
Surgical & Medical Instruments & Apparatus (3841), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIAJAB
Specialty Pharmaceutical Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYHLAIACAH
Nephrology & Urology Specialty Pharmaceuticals

Keywords

  • Medical devices
  • Barrier technology products
  • Gastrointestinal therapeutics
  • Urogynecology treatments
  • Wound healing devices

Where Noventure is headquartered

Location

Headquarters

HQ city
Barcelona
HQ country
Spain
HQ region
Europe

Offices1 record

Markets served

Noventure business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Marketing or Sales, Personnel, Others

Revenue model

  1. Licensing Royalties: Noventure's business model is based on licensing exclusive commercial rights for medical device products to distribution partners in selected geographic regions. Partners commercialize products under various local brand names and pay licensing fees or royalties to Noventure.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Noventure product offering

Product offering

Core offering

Noventure develops, patents, and licenses a portfolio of CE-marked, MDR Class III medical devices based on proprietary barrier technology using natural polymers (xyloglucan, gelatin tannate, gelose, Olea europaea leaf extract). Core products treat acute diarrhoea (Tasectan AF), urinary tract infections (Utipro Plus AF), and anal fissures (Ulkox), with additional wound-healing, nasal, and IBS-D products. The company does not sell directly; instead it grants exclusive commercial distribution rights to regional pharmaceutical partners who commercialize the products under local brand names through pharmacies in over 50 countries.

Product overview

Noventure is a Barcelona-based medical device company operating a multi-brand portfolio of clinically proven healthcare products. The core portfolio consists of three primary CE-marked medical devices: Tasectan AF (MDR Class III) for acute diarrhea, Utipro Plus AF (MDR Class III) for urinary tract infections, and Ulkox (MDR Class IIb) for anal fissure healing. All products are backed by clinical trials, included in treatment guidelines, and protected by patents. The company also markets acquired wound-healing products (Oleoabrax EHO), nasal mucoprotection (Rhinosectan), pediatric diarrhea formulations (Xilaplus AF), probiotic combinations (Tasectan Duo), and IBS-D treatment (Gelsectan). Noventure's business model is based on licensing distribution rights to regional partner companies, with products distributed across over 50 countries.

Differentiator

Problem solved

Functional benefit

Brands

  • Tasectan: Medical device for treatment of acute diarrhoea, composed of xyloglucan and gelose. MDR Class III certified.
  • Tasectan Duo
  • Utipro Plus / Utipro Plus AF
  • Ulkox
  • Xilaplus / Xilaplus AF
  • Gelsectan
  • Rhinosectan / Rinonet
  • Oleoabrax
  • Aprotecol

Products and services

  • Tasectan AF CE-marked, MDR Class III medical device composed of xyloglucan (tamarind seed extract) and gelose that forms a protective film over the intestinal mucosa to reduce frequency and duration of acute diarrhoea in children (under 3 years up to 14 years, sachets) and adults (capsules). Licensed to exclusive distribution partners worldwide.
  • Utipro Plus AF CE-marked, MDR Class III medical device based on xyloglucan and gelose that creates a protective mechanical barrier in the intestinal lumen to impair bacterial contact with mucosa, prevent adhesion of uropathogenic bacteria, and reduce recurrent urinary tract infections in adolescents (14+ years) and adults. Mentioned in EAU guidelines as non-antibiotic approach with highest level of scientific evidence.
  • Ulkox CE-marked, MDR Class IIb medical device based on Fucocert (polysaccharide), glycerine, Olea europaea leaf extract, and Carbopol 980 presented as hydrogel for the healing of anal fissures in children and adults. Components act synergistically by moisturizing the wound, scavenging free radicals, isolating the lesion, and reducing pH.
  • Oleoabrax EHO CE-marked medical device based on Olea europaea leaf extract hydrogel (EHO-85) intended for healing of full and partial thickness wounds including pressure ulcers, venous leg ulcers, and diabetic foot ulcers. Demonstrated 51.6% relative wound area reduction versus 18.9% for standard hydrogel in clinical trials.
  • Rhinosectan Class I CE-marked medical device based on xyloglucan (mucomimetic agent) that forms a protective barrier over the nasal epithelial mucosa for control and treatment of rhinitis and rhinosinusitis symptoms.
  • Xilaplus AF

Quantifiable outcome

  • Tasectan demonstrated reduction of stool frequency and improved stool consistency in children with acute diarrhea in randomized controlled trials
  • +2 more outcomes

Companies that use Noventure

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles1 record

Noventure technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Noventure partnerships and signals

Strategic signal

Partnerships

15 partnerships are on record, tiered core and regional.

  • Laboratorios Salvat, S.A.coreChannel Partner/ Reseller/ Distributor · 22 February 2018Salvat distributes Noventure's nasal mucoprotection product (Rhinosectan) in Spain and Portugal. The product is a Class I CE marked medical device based on xyloglucan for control and treatment of rhinitis and rhinosinusitis symptoms.
  • RFSU (Riksförbundet för sexuell upplysning)coreChannel Partner/ Reseller/ Distributor · 13 March 2017RFSU distributes Noventure's Utipro Plus in Nordic countries (Denmark, Finland, Iceland, Norway and Sweden). With this agreement, Utipro Plus became available in 21 European countries. RFSU is a Swedish Association for Sexuality Education and NGO founded in 1933, focused on women's health.
  • Devicare, S.L.coreChannel Partner/ Reseller/ DistributorNew partnership announced to bring Utipro Plus AF into the Spanish market. Noventure collaborates with Devicare to expand product availability in Spain.
  • PharmaforcecoreChannel Partner/ Reseller/ DistributorNoventure granted Pharmaforce exclusive distribution right for Tasectan AF in the Nordic markets (Denmark, Sweden, Finland, and Norway). Tasectan AF is intended to restore physiological functions of intestinal walls for control and reduction of diarrheal events.
  • VemediaregionalChannel Partner/ Reseller/ DistributorVemedia distributes Utipro Plus in the Netherlands and France (under the umbrella brand Cysticare/Utipro plus).
  • LapidotregionalChannel Partner/ Reseller/ DistributorLapidot is a long-term distribution partner for Utipro Plus in Israel since Q4 2017.
  • JGLregionalChannel Partner/ Reseller/ DistributorJGL distributes Tasectan in Croatia under the brand Normia Stop. Tasectan acts by forming a film that protects intestinal mucosa, reducing frequency and duration of diarrhea episodes.
  • TherabelregionalChannel Partner/ Reseller/ DistributorTherabel is a long-term partner distributing Xilaplus in France under the brand name Diastil Diarrhee.
  • Generica IlaçregionalChannel Partner/ Reseller/ DistributorNew partnership with Generica Ilaç to market Xilaplus AF in Turkey. Xilaplus AF is a Class IIa CE marked medical device for control and reduction of diarrheal events.
  • MedexportregionalChannel Partner/ Reseller/ DistributorMedexport signed an agreement for distribution of Utipro Plus AF in Kazakhstan, representing expansion into Central Asia.
  • PamexregionalChannel Partner/ Reseller/ DistributorPamex extends distribution of Utipro Plus AF to the UK, building on their existing partnership in Ireland.
  • MiecysregionalChannel Partner/ Reseller/ DistributorMiecys distributes Xilaplus in Estonia, Latvia, and Lithuania.
  • MontavitregionalChannel Partner/ Reseller/ DistributorMontavit distributes Tasectan Duo in Austria (second market after Italy by Angelini). Tasectan Duo is the first combination of gelatin tannate and inactivated bacteria.
  • JadranregionalChannel Partner/ Reseller/ DistributorJadran distributes Tasectan in Russia under the umbrella brand Adiarin. It was the first Noventure product launched in Russia.
  • ELVAregionalChannel Partner/ Reseller/ DistributorELVA launches Utipro Plus in Czech Republic, Slovak Republic, and Hungary.

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Noventure competitors and assessment

Company assessment

Direct peers

  • Ferring Pharmaceuticals: Swiss specialty pharma with strong focus on gastroenterology, urology, and reproductive health — directly overlapping with Noventure's therapeutic categories. Comparable specialty-pharma profile with patent-protected products and a global licensing/partner approach.
  • Tillotts Pharma AG: Swiss specialty pharma focused on gastroenterology (IBD, infectious diarrhea). Comparable size to Noventure with a similar specialty medical-device product strategy and European licensing/commercial model.
  • BioGaia AB: Swedish probiotics and gut-health consumer healthcare company. Comparable in therapeutic focus (gut health), consumer/medical positioning, and global partner-driven distribution model with multiple brand SKUs.

Broad incumbents

  • Menarini Group: Italian pharmaceutical group with strong consumer health and distribution network across Europe and emerging markets. Comparable mid-to-large European specialty pharma with deep licensing and distribution partnerships.
  • Almirall S.A. Spanish specialty pharma with focus on dermatology and specialty care. Comparable as a Spanish-headquartered specialty pharma with European commercial reach and licensing partnerships in adjacent therapeutic areas.
  • Italfarmaco S.p.A. Italian specialty pharma with focus on women's health, neurology, and rare diseases. Comparable specialty/OTC profile and European licensing approach, particularly relevant for women's health (UTIs).
  • Chiesi Farmaceutici S.p.A. Italian specialty pharma with focus on respiratory, neonatology, and rare diseases. Comparable European specialty-pharma profile and global licensing/partner approach.
  • Smith & Nephew plc: Global medical device company with a significant wound management franchise. Comparable to Noventure's wound-care portfolio (Ulkox/Oleoabrax) in the chronic-wound-care segment, though much larger scale.
  • Angelini Pharma: Italian specialty pharma with consumer health/OTC portfolio and licensing partnerships. Comparable specialty-medtech and licensing-driven distribution model across Europe and the Mediterranean.
  • Recordati S.p.A. Italian specialty pharma with European focus on rare diseases, urology, and specialty care. Comparable specialty pharma of similar size range operating through licensing and partner distribution in Europe.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Noventure social profiles

Digital presence

Noventure compliance and trust

Trust signal

Compliance6 records

Noventure financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Noventure leadership team

Management profile

Number of profiles

Profiles1 record

Noventure funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Noventure M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Noventure

What does Noventure do?

Noventure develops, patents, and licenses a portfolio of CE-marked, MDR Class III medical devices based on proprietary barrier technology using natural polymers (xyloglucan, gelatin tannate, gelose, Olea europaea leaf extract). Core products treat acute diarrhoea (Tasectan AF), urinary tract infections (Utipro Plus AF), and anal fissures (Ulkox), with additional wound-healing, nasal, and IBS-D products. The company does not sell directly; instead it grants exclusive commercial distribution rights to regional pharmaceutical partners who commercialize the products under local brand names through pharmacies in over 50 countries.

Is Noventure a public or private company?

Noventure is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Noventure founded?

Noventure was founded in 2014. It employs 11 to 50 people.

Where is Noventure based?

Noventure is headquartered in Barcelona, Spain, in the Europe region.

How does Noventure make money?

One revenue line is on record: licensing Royalties.

Who are Noventure's main competitors?

Direct peers on record are Ferring Pharmaceuticals, Tillotts Pharma AG and BioGaia AB. Broad incumbents are Menarini Group, Almirall S.A., Italfarmaco S.p.A., Chiesi Farmaceutici S.p.A., Smith & Nephew plc, Angelini Pharma and Recordati S.p.A..

Does Noventure have an API?

No public API is recorded for Noventure.

What industry is Noventure in?

Noventure's product category is Medical Devices. Its primary akta.pro industry code is HLAIAJAB, Specialty Pharmaceutical Distributors, with a secondary code of HLAIACAH, Nephrology & Urology Specialty Pharmaceuticals. Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals